Keep the commitment and its conditions in the same discussion

I would help directors understand what a strategic agreement leaves the business responsible for after approval. A network investment creates work to support, an acquisition can depend on permissions still controlled by others, and a funding choice changes ownership as well as cash. These are practical questions about the enterprise that will exist after the decision. My contribution would be to make those consequences clearer without turning the board into an operating-planning team or treating my strategy experience as authority over technical, clinical or legal assessment.

The most useful starting point is an investment I supported that did not work. In 2018 a remote workshop was expected to handle 250 monthly jobs; the first six months averaged ninety. We closed after eighteen months, with ₹62 lakh of startup cost unrecovered and customer-agreed transfers of responsibility. I would want a board to understand how the volume estimate became the operating case, which assumptions proved weak and how management considered its obligations when changing course. The later orderly transition was necessary, but it did not erase the failed expansion or make the operating team solely responsible for the original forecast.

The acquisition case shows a different condition of strategic responsibility. Eighteen of 26 reviewed permissions required fresh consent under the particular agreements, while eight were transferable. We declined a ₹32 crore proposal and retained ₹74 lakh of diligence cost. I would help directors connect that finding with the business the purchaser could operate after completion. I would not present it as a universal legal rule or claim that every counterparty would have refused. Qualified advisers assess the actual terms; oversight needs an intelligible account of their consequence for the commitment being proposed.

I would also examine comparisons that appear simple because the headline amounts are easy to subtract. A ₹7.2 crore company-owned spare-stock proposal and a ₹3.1 crore customer-owned setup programme created different obligations. Choosing the latter did not establish a ₹4.1 crore like-for-like saving. Twelve hospitals signed from 24 approached, and the programme account needed to preserve that scope. Directors should be able to understand who owns the assets, who funds the work and what service is being promised, rather than allow a smaller amount to imply an equivalent operating result without the supporting account.

Commercial scope can be just as consequential as capital. A proposed six-thousand-device agreement was narrowed to 2,200 devices with verified support scope, leaving 3,800 outside. The smaller agreement gave up immediate opportunity but made the commitment clearer. A board should understand how management establishes the boundaries of a material contract and how any later expansion would be assessed. It should not prescribe repairs or decide clinical use. My experience would support questions about the process and its evidence while respecting the responsibilities of technical teams, customers and other qualified decision makers.

The 2025 funding choice required a clear distinction between primary capital for the enterprise and a full-company acquisition proposal. The board selected ₹12 crore for 40%, leaving the founder family with 60%, rather than proceeding with the separate ₹27 crore full-sale offer. Planned proceeds of ₹3.6 crore for parts, ₹3.4 crore for tools and ₹5 crore for working capital were allocations, not earnings or completed expenditure. I would ask how the operating plan develops after the transaction and whether reporting keeps those states visible. The completion of funding does not complete the work it was intended to support.

I have presented proposals through the CEO but have not held a statutory appointment. A first outside role would require me to learn the receiving enterprise's finances, people, customers and sector obligations beyond the planning questions I know best. I would seek an experienced chair and complementary expertise, and ask for feedback on whether my interventions helped the collective judgement. Executive confidence should not become a substitute for that learning. I would expect to change some views as I understood the business and to contribute to decisions outside my familiar speciality with appropriate care.

My employment and commercial relationships would require disclosure and qualified review before confidential papers were shared. I hold no direct shares, but that does not settle independence or remove conflicts. Employer consent, applicable appointment requirements and a realistic assessment of twenty-four provisional days would precede acceptance. The fictional March registration and September assessment pass describe preparation only. I would decline a role if recurring exclusions or limited capacity prevented a useful contribution. The responsibility I seek is to help a board choose a supportable future enterprise, with its assumptions and obligations visible enough for collective oversight.